NCT00630058View on ClinicalTrials.gov

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Hepatitis C
Interventions
DRUG

MP-424(H), PEG-IFN-a-2b, RBV

MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks

DRUG

MP-424 (L), PEG-IFN-a-2b, RBV

MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks

Trial Locations (1)

Unknown

Toranomon Hospital, Kawasaki

Sponsors
All Listed Sponsors
collaborator

Vertex Pharmaceuticals Incorporated

INDUSTRY

lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY